Skip to main content

Table 1 Characteristics of the study groups

From: Impairment of cognitive functioning during Sunitinib or Sorafenib treatment in cancer patients: a cross sectional study

  Patients VEGFR TKI (n = 30) Patient controls (n = 20) Healthy controls (n = 30) P
Characteristics     
Age, years     
Mean 60 62 58 0.456e
Range 38-81 30-75 45-73
Sex (%)        
Male 27 (90) 15 75 26 (87) 0.329f
Female 3 (10) 5 25 4 (13)
Median education level (SD)d 4 (1.21) 5 (1.12) 5 (0.80) 0.546g
Estimation IQ (SD) 102.30 (10.37) 106.20 (10.55) 106.37 (8.09)  
Median free testosteronec pmol/L (IQR 25-75) 165.00 (129,5-238.00) 237.50 (200.75-299.25) - - 0.005a
Median estradiol pmol/l (IQR 25-75) 48.00 (42-55) 78.50 (78.5-112.5) - - 0.000 a
Median albumin g/l (IQR 25-75) 39.00 (34.50-40.25) 37.50 (35.25-40.00) - - 0.599a
Median CRP mg/l (IQR 25-75) 10.00 (4.00-21.75) 5.00 (4.00-38.25) - - 0.849a, b
Median absolute neutrophil count 109/l (IQR 25-75) 2.95 (2.08-3.66) 3,89 (3.43-5.64) - - 0.009a
Median ESR mm/hour (IQR 25-75) 20.00 (8.75-34.50) 19.00 (7.00-31.00) - - 0.767a, b
Median glucose mmol/l (IQR 25-75) 5.6 (4.9-5.98) 5.8 (5.35-7.55) - - 0.010a
Median TSH mE/l (IQR 25-75) 2.29 (1.49-3.63) 1.12 (0.78-2.04) - - 0.003a, b
Median LDH U/l (IQR 25-75) 463.50 (402.25-526.50) 346.50 (314.50-458.00) - - 0.008a, b
Median VEGF ng/ml (IQR 25-75) 1.62 (1.09-2.18) 1.48 (1.21-2.00) - - 0.221a
  1. aT-test between the two patients groups; bcalculated with the logaritmic values.
  2. ccalculated free testosterone only in men, reference value for men: 120-630 pmol/l, estradiol level only in men, reference value 75-220 pmol/l. Abbreviations: SD Standard deviation, IQR inter quartile range 25e and 75e percentile, ESR erythrocyte sedimentation rate, CRP C-reactive protein, LDH lactate dehydrogenase, VEGF vascular endothelial growth factor.
  3. dEducation levels as assessed using 7 categories in accordance with the Dutch educational system (1 = less than primary school; 7 = academic degree); eANOVA; fChi-square test; gKruskal-Wallis Test.